GBT Global Blood Therapeutics Inc.

42.24
-0.37  -1%
Previous Close 42.61
Open 42.09
Price To Book 4.67
Market Cap 2206298604
Shares 52,232,448
Volume 962,331
Short Ratio
Av. Daily Volume 1,463,093

SEC filingsSee all SEC filings

  1. 8-K - Current report 181231045
  2. 424B5 - Prospectus [Rule 424(b)(5)] 181227840
  3. 424B5 - Prospectus [Rule 424(b)(5)] 181220803
  4. 8-K - Current report 181214055
  5. 8-K - Current report 181214053

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a discontinuation announced October 23, 2017 due to lack of efficacy.
GBT440
Hypoxemia in patients with idiopathic pulmonary fibrosis (IPF) who are on supplemental oxygen at rest
Pre-NDA meeting scheduled for 1Q 2019. NDA to be filed under accelerated approval.
GBT440
Sickle cell disease
Phase 2 data to be presented at ASH December 3, 2018 noted 55% (6 of 11) achieved a hemoglobin response >1 g/dL .
GBT440 HOPE-KIDS 1
Sickle cell disease - children age 6-17.

Latest News

  1. Ghost Tree Capital’s AUM, Returns and Holdings
  2. Here's Why Global Blood Therapeutics Fell 10.1% in November, Then Jumped 37% Since
  3. Global Blood Therapeutics, Voxelotor in Advanced Clinicals, Analysts Review and Target
  4. Global Blood Therapeutics Prices a $150.0 Million Common Stock Public Offering
  5. The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut
  6. 3 Biotech Stocks That Could Explode Higher in 2019
  7. Global Blood Therapeutics Announces Proposed Public Offering of Common Stock
  8. 3 Top Stocks After #ASH18
  9. Jim Cramer Advises His Viewers On Adobe, Barnes & Noble And More
  10. Cramer's lightning round: Barnes & Noble's stock is trading like it could get acquired
  11. GBT Announces New Employment Inducement Grants
  12. Company News For Dec 4, 2018
  13. Stocks Jump 1% on 90-Day Tariff Delay
  14. Global Blood Therapeutics' Voxelotor on Faster Approval Path
  15. Today's Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Global Blood Therapeutics
  16. Global Blood's Sickle Cell Disease Drug Snags Accelerated FDA Approval Pathway
  17. Why Global Blood Therapeutics Skyrocketed Today
  18. Global Blood Therapeutics stock up 40% after FDA agrees to accelerated approval pathway for sickle cell disease drug
  19. GBT Announces Positive 24-week Results from Phase 3 HOPE Study Demonstrating Clinically and Statistically Significant Improvements in Hemoglobin and Clinical Measures of Hemolysis and a Favorable Safety Profile

SEC Filings

  1. 8-K - Current report 181231045
  2. 424B5 - Prospectus [Rule 424(b)(5)] 181227840
  3. 424B5 - Prospectus [Rule 424(b)(5)] 181220803
  4. 8-K - Current report 181214055
  5. 8-K - Current report 181214053
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163085
  7. 8-K - Current report 181162974
  8. 8-K - Current report 181047101
  9. 8-K - Current report 181033687
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 18988470